- Trials with a EudraCT protocol (2,368)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2,368 result(s) found for: Neoplasms AND Metastatic Cancer.
Displaying page 84 of 119.
EudraCT Number: 2018-004329-10 | Sponsor Protocol Number: UKM17_0018 | Start Date*: 2020-07-09 | |||||||||||
Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel | |||||||||||||
Full Title: A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy | |||||||||||||
Medical condition: High risk adenocarcinoma of the prostate after radical prostatectomy (RPE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003716-47 | Sponsor Protocol Number: GCT1042-01 | Start Date*: 2019-07-02 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety and anti-tumor activity of GEN1042 in subjects with malignant solid tumors | |||||||||||||
Medical condition: Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer (CRC) who are not anymore candidates for ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) DE (Trial now transitioned) ES (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002080-18 | Sponsor Protocol Number: AIO-STO-0417 | Start Date*: 2018-06-12 | |||||||||||
Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |||||||||||||
Full Title: Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs. FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction –... | |||||||||||||
Medical condition: advanced or metastatic adenocarcinoma of the esophagogastric junction or the stomach | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021587-15 | Sponsor Protocol Number: ICORG10-04NSABP-B46I | Start Date*: 2010-09-08 | |||||||||||
Sponsor Name:ICORG | |||||||||||||
Full Title: A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | |||||||||||||
Medical condition: Adjuvant Breast Cancer: Node positive or high risk node negative and HER 2 negative | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004070-26 | Sponsor Protocol Number: BRICE | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | |||||||||||||
Full Title: A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer a... | |||||||||||||
Medical condition: Advanced or metastatic epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to approved EGFR tyrosine kinase inhibitors (TKI); advan... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002504-41 | Sponsor Protocol Number: B7461027 | Start Date*: 2020-07-17 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyros... | |||||||||||||
Medical condition: ALK-positive metastatic non-small-cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006209-17 | Sponsor Protocol Number: I2I-MC-JMMC | Start Date*: 2011-07-05 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer | ||
Medical condition: Phase I: Patients with solid malignancy unlikely to benefit from approved therapies. Phase II: Patients with pancreatic cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) SK (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005848-16 | Sponsor Protocol Number: CS7017-A-E201 | Start Date*: 2009-06-16 | |||||||||||
Sponsor Name:Daiichi Sankyo Development Ltd | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 2 STUDY OF CS-7017 IN COLORECTAL CANCER PATIENTS WHO HAVE ACHIEVED DISEASE CONTROL FOLLOWING FIRST-LINE CHEMOTHERAPY | |||||||||||||
Medical condition: Stage III and IV Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004284-51 | Sponsor Protocol Number: ESR-18-14159 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:Amsterdam UMC, VU University Medical Center | |||||||||||||
Full Title: An exploratory study of durvalumab (MEDI4736) uptake during concurrent chemoradiotherapy in stage III NSCLC patients using 89Zr-labeled durvalumab PET | |||||||||||||
Medical condition: Lung cancer, NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003932-38 | Sponsor Protocol Number: 50797 | Start Date*: 2016-03-30 | |||||||||||
Sponsor Name:VU University medical center (VUmc) | |||||||||||||
Full Title: Advanced imaging in laparoscopic HIPEC for peritoneal carcinomatosis of colorectal orgin to improve cytoreduction; a feasibility study | |||||||||||||
Medical condition: Peritoneal carcinomatosis from colorectal origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000777-38 | Sponsor Protocol Number: SOAP | Start Date*: 2014-06-19 | |||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori | |||||||||||||
Full Title: Activity and safety of second line SOrafenib After Pazopanib in patients with metastatic renal cell carcinoma (SOAP Study) | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000155-21 | Sponsor Protocol Number: UC-0160/1702 | Start Date*: 2019-07-23 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: An open label, randomized, phase III study, evaluating the efficacy of a Combination of Apalutamide with Radiotherapy and LHRH Agonist in high-risk postprostatectomy biochemically relapsed prostate... | |||||||||||||
Medical condition: High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004942-16 | Sponsor Protocol Number: D791LC00001 | Start Date*: 2012-02-22 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy... | |||||||||||||
Medical condition: Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000475-27 | Sponsor Protocol Number: I14041 | Start Date*: 2015-07-29 | |||||||||||
Sponsor Name:CHU de Limoges | |||||||||||||
Full Title: Multicenter phase II trial of Nintedanib plus docetaxel in second line of treatment in patients with no squamous non small cell lung cancer refractory to first line chemotherapy (REFRACT study) | |||||||||||||
Medical condition: No squamous non small cell lung | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004389-37 | Sponsor Protocol Number: FG001-CT-002 | Start Date*: 2022-03-24 | |||||||||||
Sponsor Name:FluoGuide A/S | |||||||||||||
Full Title: An open-label, non-randomized, single dose, exploratory Phase II trial of FG001 (an imaging agent) for localization of biopsy-proven primary non-small cell lung cancer (NSCLC) | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005223-21 | Sponsor Protocol Number: D926PC00001 | Start Date*: 2022-06-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in Firs... | |||||||||||||
Medical condition: Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002941-36 | Sponsor Protocol Number: M11TCR | Start Date*: 2012-04-02 | |||||||||||
Sponsor Name:NKI-AVL | |||||||||||||
Full Title: Multicenter phase 1/2a study using T-cell receptor gene therapy in metastatic melanoma | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023050-37 | Sponsor Protocol Number: TRICC-C | Start Date*: 2011-05-20 | |||||||||||
Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | |||||||||||||
Full Title: A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal ca... | |||||||||||||
Medical condition: Patients with chemorefractory colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000875-34 | Sponsor Protocol Number: MM1807 | Start Date*: 2018-05-30 | |||||||||||
Sponsor Name:National Center for Cancer Immune Therapy | |||||||||||||
Full Title: Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids | |||||||||||||
Medical condition: Metastatic melanoma with brain metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004418-32 | Sponsor Protocol Number: TestisCAB | Start Date*: 2016-03-16 | |||||||||||
Sponsor Name:Oslo University Hospital - Cancer Department | |||||||||||||
Full Title: Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer. | |||||||||||||
Medical condition: Cisplatin-resistant germ cell cancer of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) DK (Completed) SE (Ongoing) NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
